FundingWatcher
Home / Startups / Top biotech startups / Biotech startups in Massachusetts, United States

Biotech startups in Massachusetts, United States

Updated 16 Nov 2026

Reset
Biotech startups in Massachusetts, United States
One-time CSV
  • 751 funded companies, 648 with a website
  • Last round, amount, date, total raised and investors
  • CRM-ready CSV, 18 columns
  • Download right after payment
With founder contacts
Compiled to order
  • The full startup CSV, plus founders and executives
  • Up to 2 founders or CEOs per company, compiled to order
  • Name, job title and LinkedIn URL where found
  • Verified direct email per person
  • Startup CSV at once, contacts CSV by mail within 24 hours
Download right after paymentFree 10-row sampleSecure checkout by Stripe

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

startups-biotech~massachusetts-united-states.csv751 rows × 18 columns
CompanyCityLast roundAmountDate
Insilico MedicineCambridgeSeries E$123.0M2025-03-13
Ratio TherapeuticsBostonSeries C$70.0M2026-07-31
NeurableBostonSeries A$35.0M2025-12-19
VideaHealthBostonSeries B$40.0M2025-01-28
ConcertAICambridgeSeries C$150.0M2022-03-29
Ascidian TherapeuticsBostonSeries A$40.0M2023-11-08
Biobot AnalyticsCambridgeSeries A$13.4M2025-06-06
Dyno TherapeuticsCambridgeSeries A$100.0M2021-05-06

8 rows of the CSV in 5 of its 18 columns.

751
Startups
$47.7B
Total raised
118
Funded in the last 12 months
$4.3B
Raised in the last 12 months

Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.

Newest rounds

30 of 751
30 rows
Company What they do Sector City Last round Amount Date Total raised Investors Employees Founded
Delix Therapeutics Delix Therapeutics develops psychoplastogen therapies that promote neuroplasticity. Biotech Boston Series C $100.0M 2026-11-09 $244.1M Gaingels, RA Capital Management, Dolby Family Ventures +2 11 to 50 2019
Arkea Bio Arkea Bio develops technology that reduces greenhouse gas emissions from agriculture. Biotech Charlestown Series A $15.0M 2026-09-29 $60.5M Breakthrough Energy Ventures, Overview, Rabo Ventures 11 to 50 2021
Alzheon Alzheon develops treatments for neurodegenerative disorders as a clinical-stage biotechnology company. Biotech Framingham Series F $78.8M 2026-09-10 $343.3M Ally Bridge Group, National Institute on Aging 11 to 50 2013
INIA Biosciences INIA Biosciences develops non-invasive, home-administered medical devices to manage chronic inflammatory diseases. Biotech Boston Seed $1.5M 2026-09-08 $1.5M MassChallenge, MedTech Innovator 1 to 10 2020
Superluminal Medicines Superluminal Medicines develops small-molecule therapeutics by combining AI, biology, and chemistry. Artificial intelligence Boston Series B $65.5M 2026-09-03 $223.5M Insight Partners, RA Capital Management, NVentures 11 to 50 2022
Simnova Simnova Biotherapeutics develops CAR-based cell therapies for treating cancer. Biotech Cambridge Series B $59.3M 2026-08-18 $87.2M Oriza Seed Capital (Oriza Yuandian), Youshan Capital, PagodaTree Partners +1 51 to 100 2019
Remedium Bio Remedium Bio develops gene therapy treatments for various diseases. Biotech Needham Series A $10.0M 2026-08-10 $13.8M National Science Foundation, MicroVentures, Longevitytech.fund +1 11 to 50 2020
Dash Bio Dash Bio develops automated laboratory workflows and software to support drug development through bioanalysis services. Artificial intelligence Boston Series A $30.0M 2026-08-03 $47.5M Freestyle Capital, Swift Ventures, LifeX Ventures +1 11 to 50 2024
Ratio Therapeutics Ratio Therapeutics develops radiopharmaceuticals to treat solid tumors in clinical trials. Biotech Boston Series C $70.0M 2026-07-31 $160.0M Bristol-Myers Squibb, The Pags Group, Schusterman Family Investments 11 to 50 2021
Xellar Biosystems Xellar Biosystems analyzes drug testing and treatment data using artificial intelligence. Artificial intelligence Newton Series A $29.5M 2026-06-30 $93.2M Legend Capital, Tiantu Capital, Zhengxuan Investment +1 11 to 50 2022
Portal Portal engineers cells to develop new treatments and therapies. Biotech Watertown Seed $9.0M 2026-06-18 $25.7M Pear VC, Page One Ventures, IA Ventures +2 11 to 50 2023
Triveni Bio Triveni Bio develops antibody-based therapeutics for immunological and inflammatory diseases. Biotech Watertown Series C $65.0M 2026-06-17 $272.0M Polaris Partners, OrbiMed, Alexandria Venture Investments +2 11 to 50 2019
CereVasc CereVasc develops a minimally invasive treatment for communicating hydrocephalus. Biotech Charlestown Series C $85.0M 2026-06-04 $199.0M Perceptive Advisors, Bain Capital Life Sciences, ATON Partners 11 to 50 2014
Elemental Machines Elemental Machines provides data-driven insights to improve research, laboratory operations, and manufacturing outcomes. Artificial intelligence Cambridge Series B $5.7M 2026-05-27 $66.5M Founders Fund, Tau Ventures, Rock Health Capital +2 11 to 50 2015
Cerevance Cerevance develops novel therapeutics for neurological diseases. Biotech Boston Series C $20.0M 2026-05-12 $209.5M Google Ventures, Casdin Capital, Foresite Capital +1 51 to 100 2016
Kytopen Kytopen develops genome engineering platforms for cell therapy research and manufacturing. Biotech Cambridge Series B $1.6M 2026-04-07 $39.1M National Science Foundation, MassVentures, Alexandria Venture Investments +1 11 to 50 2017
Terrestrial Bio Terrestrial Bio develops biomedical innovations aimed at improving access to vaccines. Biotech Cambridge Series C $50.0M 2026-03-26 $180.9M RA Capital Management, National Institutes of Health, The Engine 11 to 50 2012
Cognito Therapeutics Cognito Therapeutics develops neurotechnology therapies that stimulate brain activity to treat neurodegenerative diseases. Biotech Cambridge Series C $105.0M 2026-03-05 $321.8M Morningside, FoundersX Ventures, IAG Capital Partners +1 11 to 50 2016
Atavistik Bio Atavistik Bio develops precision allosteric small molecules to treat metabolic diseases and cancer. Biotech Cambridge Series B $40.0M 2026-03-05 $260.0M Lux Capital, The Column Group, Nextech Invest 11 to 50 2021
Stata DX Stata DX develops eRapid disease management technology for implementing custom biomarker panels in clinical studies. Biotech Cambridge Series A $400K 2026-02-27 $3.6M MassVentures 1 to 10 2022
Gelmedix Gelmedix develops a biomaterial platform that improves drug delivery for complex eye treatments. Biotech Newton Seed $13.0M 2026-02-17 $15.4M Safar Partners, EQx Fund, HTL Innovations 1 to 10 2020
Third Arc Bio Third Arc Bio develops multifunctional antibodies for inflammatory and immunology diseases. Biotech Boston Series A $52.0M 2026-02-04 $217.0M T. Rowe Price, Cormorant Asset Management, Foresite Capital +1 11 to 50 2022
Precede Biosciences Precede Biosciences develops blood-based tests that reveal disease-defining transcriptional biology. Biotech Boston Series B $63.5M 2026-01-12 $140.5M Bristol-Myers Squibb, Lilly Asia Ventures, 5AM Ventures +2 11 to 50 2005
Diagonal Therapeutics Diagonal Therapeutics develops targeted therapies for cancer and genetic diseases. Biotech Watertown Series B $125.0M 2026-01-08 $253.0M Lightspeed Venture Partners, RA Capital Management, Atlas Venture +1 11 to 50 2022
Nocion Therapeutics Nocion Therapeutics develops pharmaceuticals to treat conditions arising from neurogenic inflammation. Biotech Cambridge Series B $23.0M 2026-01-07 $134.0M Canaan Partners, F-Prime, OUP (Osage University Partners) +2 11 to 50 2017
Prudentia Sciences Prudentia Sciences provides AI-powered asset diligence and valuation to reduce risk in drug development investment. Artificial intelligence Cambridge Series A $20.0M 2026-01-07 $27.0M Google Ventures, Iaso Ventures, Virtue 1 to 10 2023
STRM.BIO STRM.BIO is a biotechnology company that uses extracellular vesicles to deliver gene therapy. Biotech Cambridge Seed $8.0M 2026-01-07 $10.1M Bill & Melinda Gates Foundation, NYBC Ventures, NCATS 11 to 50 2019
Myrtelle Myrtelle is a gene therapy company that runs clinical trials for rare monogenetic disorders. Biotech Wakefield Series B $30.5M 2025-12-23 $57.6M Panacea Venture 11 to 50 2020
Neurable Neurable develops AI tools for translating brain signals and brain-computer interface technology. Artificial intelligence Boston Series A $35.0M 2025-12-19 $57.3M National Science Foundation, Global Brain Corporation, Metaplanet +1 11 to 50 2015
Biometry Biometry develops diagnostic tools for patients with chronic respiratory conditions. Artificial intelligence Boston Seed $2.2M 2025-12-19 $7.8M MassChallenge, Elevate Ventures, Sidecar Angels +1 11 to 50 2013

Table 1. Biotech startups in Massachusetts, United States: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 751.

Largest rounds

Last 12 months
10 rows
# Company What they do Sector City Last round Amount Date Total raised Investors Employees Founded
1 Diagonal Therapeutics Diagonal Therapeutics develops targeted therapies for cancer and genetic diseases. Biotech Watertown Series B $125.0M 2026-01-08 $253.0M Lightspeed Venture Partners, RA Capital Management, Atlas Venture +1 11 to 50 2022
2 Sanegene Bio Sanegene Bio develops an RNAi drug discovery platform aimed at unmet clinical needs. Biotech Woburn Series B $110.0M 2025-12-08 $240.0M Shenzhen Capital Group, Qiming Venture Partners, Northern Light Venture Capital +1 51 to 100 2021
3 Cognito Therapeutics Cognito Therapeutics develops neurotechnology therapies that stimulate brain activity to treat neurodegenerative diseases. Biotech Cambridge Series C $105.0M 2026-03-05 $321.8M Morningside, FoundersX Ventures, IAG Capital Partners +1 11 to 50 2016
4 Delix Therapeutics Delix Therapeutics develops psychoplastogen therapies that promote neuroplasticity. Biotech Boston Series C $100.0M 2026-11-09 $244.1M Gaingels, RA Capital Management, Dolby Family Ventures +2 11 to 50 2019
5 CereVasc CereVasc develops a minimally invasive treatment for communicating hydrocephalus. Biotech Charlestown Series C $85.0M 2026-06-04 $199.0M Perceptive Advisors, Bain Capital Life Sciences, ATON Partners 11 to 50 2014
6 Alzheon Alzheon develops treatments for neurodegenerative disorders as a clinical-stage biotechnology company. Biotech Framingham Series F $78.8M 2026-09-10 $343.3M Ally Bridge Group, National Institute on Aging 11 to 50 2013
7 Ratio Therapeutics Ratio Therapeutics develops radiopharmaceuticals to treat solid tumors in clinical trials. Biotech Boston Series C $70.0M 2026-07-31 $160.0M Bristol-Myers Squibb, The Pags Group, Schusterman Family Investments 11 to 50 2021
8 Superluminal Medicines Superluminal Medicines develops small-molecule therapeutics by combining AI, biology, and chemistry. Artificial intelligence Boston Series B $65.5M 2026-09-03 $223.5M Insight Partners, RA Capital Management, NVentures 11 to 50 2022
9 Triveni Bio Triveni Bio develops antibody-based therapeutics for immunological and inflammatory diseases. Biotech Watertown Series C $65.0M 2026-06-17 $272.0M Polaris Partners, OrbiMed, Alexandria Venture Investments +2 11 to 50 2019
10 Precede Biosciences Precede Biosciences develops blood-based tests that reveal disease-defining transcriptional biology. Biotech Boston Series B $63.5M 2026-01-12 $140.5M Bristol-Myers Squibb, Lilly Asia Ventures, 5AM Ventures +2 11 to 50 2005

Table 2. Biotech startups in Massachusetts, United States: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most active investors

By companies backed
#InvestorTypeLocation CompaniesShare Funded, 12 monthsLatest
1 RA Capital Management Startup incubator Boston, United States 12 2% 4 Delix Therapeutics, Superluminal Medicines, Terrestrial Bio
2 Google Ventures Corporate venture arm San Francisco, United States 9 1% 2 Cerevance, Prudentia Sciences
3 National Science Foundation Entrepreneurship program Alexandria, United States 8 1% 3 Remedium Bio, Kytopen, Neurable
4 F-Prime Venture capital firm Cambridge, United States 7 1% 1 Nocion Therapeutics
5 Y Combinator Startup accelerator Mountain View, United States 7 1%
6 Alexandria Venture Investments Venture capital firm Pasadena, United States 7 1% 2 Triveni Bio, Kytopen
7 MassChallenge Startup accelerator Boston, United States 7 1% 2 INIA Biosciences, Biometry
8 Polaris Partners Private equity firm Boston, United States 6 1% 1 Triveni Bio
9 Andreessen Horowitz Venture capital firm Menlo Park, United States 5 1%
10 Invus Private equity firm New York, United States 5 1% 1 Triveni Bio
11 Alumni Ventures Angel group Manchester, United States 5 1%
12 ARCH Venture Partners Venture capital firm Chicago, United States 5 1%
13 Qiming Venture Partners Venture capital firm Shanghai, China 4 1% 1 Sanegene Bio
14 Bristol-Myers Squibb Venture capital firm New York, United States 4 1% 2 Ratio Therapeutics, Precede Biosciences
15 Pillar VC Venture capital firm Boston, United States 4 1%

Table 3. Biotech startups in Massachusetts, United States: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Sectors

SectorsCompaniesShareTotal raised
Health care 652 87% $43.6B
Software 109 15% $5.7B
Artificial intelligence 70 9% $4.4B
Hardware 24 3% $755.8M
Commerce 3 0% $75.6M
Energy 3 0% $7.8M
Education 2 0% $42.7M
Cybersecurity 2 0%
Fintech 2 0% $155K

Table 4. Biotech startups in Massachusetts, United States by sector. Source: FundingWatcher. Data as of 16 November 2026.

Funding stage

Funding stageCompaniesShareMedian last round
Pre-seed 44 6% $500K
Seed 206 27% $2.2M
Series A 223 30% $26.0M
Series B 168 22% $41.3M
Series C 70 9% $48.0M
Series D+ 40 5% $47.1M

Table 5. Biotech startups in Massachusetts, United States by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Cities

CitiesCompaniesShare
Cambridge 272 36%
Boston 211 28%
Waltham 37 5%
Watertown 26 3%
Woburn 23 3%
Lexington 19 3%
Newton 14 2%
Somerville 10 1%
Natick 10 1%
Allston 8 1%
Framingham 7 1%
Worcester 6 1%

Table 6. Biotech startups in Massachusetts, United States by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.

Rounds by month

Rounds by monthCompaniesShareRaised
November 2026 5 4% $171.8M
October 2026 6 5% $340.9M
September 2026 12 10% $473.4M
August 2026 12 10% $444.1M
July 2026 4 3% $128.0M
June 2026 15 13% $536.1M
May 2026 4 3% $149.7M
April 2026 11 9% $403.2M
March 2026 12 10% $341.1M
February 2026 4 3% $65.4M
January 2026 19 16% $640.5M
December 2025 10 8% $387.6M
November 2025 4 3% $199.7M

Table 7. Biotech startups in Massachusetts, United States: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most recent round by year

Most recent round by yearCompaniesShareRaised
2026 104 14% $3.7B
2025 98 13% $4.2B
2024 67 9% $3.0B
2023 65 9% $3.8B
2022 68 9% $3.1B
2021 74 10% $2.8B

Table 8. Biotech startups in Massachusetts, United States by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Founding year

Founding yearCompaniesShare
2023 or later 95 13%
2020 to 2022 169 23%
2015 to 2019 244 33%
2010 to 2014 110 15%
Before 2010 126 17%

Table 9. Biotech startups in Massachusetts, United States by founding year. Source: FundingWatcher. Data as of 16 November 2026.

Team size

Team sizeCompaniesShare
1 to 10 250 34%
11 to 50 341 46%
51 to 100 82 11%
101 to 250 41 6%
251 to 500 10 1%
501 to 1,000 6 1%
1,001 to 5,000 2 0%
5,001 to 10,000 1 0%
10,001 or more 2 0%

Table 10. Biotech startups in Massachusetts, United States by headcount. Source: FundingWatcher. Data as of 16 November 2026.

Method

Sources, fields and exclusions of both files: Method.

Questions

How many biotech startups in Massachusetts, United States are on the list?
751, in the file dated 16 November 2026. 118 of them closed their most recent round in the last 12 months.
What does the CSV contain?
One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
How much does the list cost?
$29 one-time for all 751 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $349.
What arrives after payment?
At once: the CSV download link, on the page after payment and by mail.
Can I see rows before buying?
The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
How current is the data?
The file is dated 16 November 2026. The download link serves the current file each time it is opened.

Biotech startups in Massachusetts, United States: 751 rows, CSV, $29 one-time.

At once: the CSV download link, on the page after payment and by mail.

Columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.

With founder contacts: $349 one-time. List CSV right after payment; up to 2 verified founder or CEO emails per company compiled to order within 24 hours.

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

Biotech startups in Massachusetts, United States by funding stage

Other sectors in Massachusetts

Biotech startups elsewhere

Cite: FundingWatcher, 751 funded biotech companies in Massachusetts, United States, 16 November 2026. https://fundingwatcher.com/startups/biotech/massachusetts-united-states/